Six years after failing phase III cobitolimod underwhelms in phase II, but Index ploughs on into a fresh pivotal study.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
Adjuvant and neoadjuvant settings are an important target for Roche’s Tecentriq, but how likely is the drug to become broadly applicable?
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.